

National Progress Report on Hepatitis C Virus (HCV) - Survey Responses

Questions	Countries
	Indonesia
Month and year of report	August 2016
1) What are the top three genotypes in your country?	Genotype 1, 2, 3
2) Please indicate the prevalence of the above top three genotypes in percentage.	
3) If you do not know the answer of question 1, please list the main genotype and its percentage of prevalence.	Genotype 1= 66.97% and 2=21.27%
Screening, Diagnosis and Care	
4) Does the government provide free or subsidized HCV antibody testing for the "general population?" 4a) If yes, what percentage of the cost is covered by the government?	YES 51% - 70%
5) Does the government provide free or subsidized HCV antibody testing for "PLHIV?" 5a) If yes, what percentage of the cost is covered by the government?	YES 71%-100%
6) Does the government provide free or subsidized HCV antibody testing for "PWID/PWUD?" 6a) If yes, what percentage of the cost is covered by the government?	Yes 71%-100%
7) Does the government provide free or subsidized HCV PCR/viral load for confirmatory testing for the "general population?" 7a) If yes, what percentage of the cost is covered by the government?	Yes 71%-100%
8) Does the government provide free or subsidized HCV PCR/viral load for confirmatory testing for "PLHIV?" 8a) If yes, what percentage of the cost is covered by the government?	NO
9) Does the government provide free or subsidized HCV PCR/viral load for confirmatory testing for "PWID/PWUD?" 9a) If yes, what percentage of the cost is covered by the government?	NO
10) Does the government provide free or subsidized clinical liver assessment for the "general population?" 10a) If yes, what percentage of the cost is covered by the government?	NO

National Progress Report on Hepatitis C Virus (HCV) - Survey Responses

Questions	Countries
	Indonesia
11) Does the government provide free or subsidized clinical liver assessment for "PLHIV?" 11a) If yes, what percentage of the cost is covered by the government?	NO
12) Does the government provide free or subsidized clinical liver assessment for "PWID/PWUD?" 12a) If yes, what percentage of the cost is covered by the government?	NO
13) Does the government provide free or subsidized FibroScan for those with confirmed active chronic HCV infection for "general population?"	NO
14) Does the government provide free or subsidized FibroScan for those with confirmed active chronic HCV infection for "PLHIV?"	NO
15) Does the government provide free or subsidized FibroScan for those with confirmed active chronic HCV infection for "PWID/PWUD?"	NO
16) Does the government provide free or subsidized genotype testing for "general population?" 16a) If yes, what percentage of the cost is covered by the government?	NO
17) Does the government provide free or subsidized genotype testing for "PLHIV?" 17a) If yes, what percentage of the cost is covered by the government?	NO
18) Does the government provide free or subsidized genotype testing for "PWID/PWUD?" 18a) If yes, what percentage of the cost is covered by the government?	NO

National Progress Report on Hepatitis C Virus (HCV) - Survey Responses

Questions	Countries
	Indonesia
<i>Additional comments on screening and diagnosis:</i>	<p>If a person have the Health insurance under JKN, which is the national Health insurance, then they will be provided the treatment using pegylated interferon. However, There is a clear lack of information on this both among physicians and patients. JKN has ceiling amount that can be paid and most of the diagnostics such as PCR, Fibroscan and Genotyping are above the ceiling amount. PCR testing is provided if the person is confirmed to take treatment under UHC. There has to be reduction in the cost of the diagnostics of these are to be covered by JKN. Government also needs initiate programs and activities to improve awareness and</p>

National Progress Report on Hepatitis C Virus (HCV) - Survey Responses

Questions	Countries
	Indonesia
Registration and patenting of direct-acting antivirals (DAA) (*NA=Information Not available)	
19) Have any of the below DAAs been filed for registration in your country? 19a) Sofosbuvir 19b) Ledipasvir 19c) Daclatasvir	Yes NO NO
20) Have patent application(s) been filed in your country for the below DAAs? 20a) Sofosbuvir 20b) Ledipasvir 20c) Daclatasvir	Yes Yes NO
21) Have any patent application(s) been granted for the below DAAs in your country? 21a) Sofosbuvir 21b) Ledipasvir 21c) Daclatasvir	Yes NO NO
22) Is a generic option available in your country for the below 22a) Sofosbuvir 22b) Ledipasvir 22c) Daclatasvir	Yes Yes Yes
<i>Additional comments on registration and patenting of DAA:</i>	Sofosbuvir has just been approved (1 July 2016) by the national drug regulator (BPOM). Though the formal registration of other DAAs have not been approved as yet, sofosbuvir/ledipasvir and daclatasvir is imported to the country under special assistance scheme which is allowed by the national regulatory body.
Treatment Access (**Please use the additional comment section if you need more space)	

National Progress Report on Hepatitis C Virus (HCV) - Survey Responses

Questions	Countries
	Indonesia
23) Does the government provide free or subsidized HCV treatment for the "general population?" 23a) If yes, what percentage of the cost is covered by the government?	YES 51% - 70%
24) Does the government provide free or subsidized HCV treatment for "PLHIV?" 24a) If yes, what percentage of the cost is covered by the government?	YES 51% - 70%
25) Does the government provide free or subsidized HCV treatment for "PWID/PWUD?" 25a) If yes, what percentage of the cost is covered by the government?	YES 51% - 70%
26) If yes, what is the government-provided treatment regimen?	
26a) Pegylated interferon (General population)	YES
26a) Pegylated interferon (PLHIV)	YES
26a) Pegylated interferon (PWID/PWUD)	YES
26b) Ribavirin (General population)	YES
26b) Ribavirin (PLHIV)	YES
26b) Ribavirin (PWID/PWUD)	YES
26c) Sofosbuvir (General population)	NO
26c) Sofosbuvir (PLHIV)	NO
26c) Sofosbuvir (PWID/PWUD)	NO
26d) Ledipasvir (General population)	NO
26d) Ledipasvir (PLHIV)	NO
26d) Ledipasvir (PWID/PWUD)	NO
26e) Daclatasvir (General population)	NO
26e) Daclatasvir (PLHIV)	NO
26e) Daclatasvir (PWID/PWUD)	NO

National Progress Report on Hepatitis C Virus (HCV) - Survey Responses

Questions	Countries
	Indonesia
<i>Additional comments on treatment access:</i>	There is a need to focus on the coverage of available DAAs in the national essential medicine list which will allow it to be covered under the national insurance program. Currently, only peg interferon based treatment can be availed only by people who have the Health insurance cards
Voluntary License	
27) Is your country included in Gilead's current voluntary license on sofosbuvir?	YES
28) Is your country included in MPP's current voluntary license on daclatasvir?	YES
<i>Any additional comments not covered but important to highlight for improving treatment access</i>	More advocacy work to include DAAs in the list of Indonesian essential medicine list need to be conducted. This work need to include all relevant stakeholder from government, non government, community and civil society organizations.